Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
After scientific advisors recommended that the US regulator not approve a new amyotrophic lateral sclerosis (ALS) therapy, developer BrainStorm Cell Therapeutics has opted to withdraw its submission. 19 October 2023
Sino-American biotech BeiGene became the first Chinese-origin pharma company to market a programmed cell death protein 1 (PD1) therapy for oncology indications in various global markets, beginning with the European Union. 18 October 2023
Shares USA-based clinical-stage biotech Evelo Biosciences plummeted 59% to $1.20 yesterday, as it announced disappointing top-line results from its Phase II clinical study with EDP2939 in moderate psoriasis. 18 October 2023
A firm in Massachusetts, USA, has won approval for a new kind of medicine, a phosphate absorption blocker, which will be used to treat certain people with chronic kidney disease (CKD). 18 October 2023
US antiviral-focused biotech Assembly Biosciences saw its share price rocket nearly 95% to $1.42, on news of a research collaboration with Gilead Sciences. 17 October 2023
Spanish genetic medicines company SpliceBio has signed an exclusive collaboration and licensing agreement with Spark Therapeutics, which was acquired by Swiss pharma giant Roche in a $4.8 billion deal in 2020, to utilize SpliceBio’s proprietary Protein Splicing platform to develop a gene therapy for an undisclosed inherited retinal disease. 17 October 2023
In what the company said was a big day for Monte Rosa Therapeutics, a clinical-stage biotech company developing novel molecular glue degrader (MGD)-based medicines, the company announced two major milestones. 17 October 2023
Chicago, USA-based artificial intelligence and antibody specialist SparX Biopharmaceutical is to embark on a new strategic collaboration with Arovella Therapeutics. 17 October 2023
Seattle, USA-based biotech Omeros Corporation saw its shares plummet as much as 58% to an all-time low of $0.92 yesterday, after it said it will discontinue development of an experimental therapy to treat a type of kidney disease after a late-stage study failure. 17 October 2023
Danish company Novo Nordisk has agreed to acquire ocedurenone - a drug in development for uncontrolled hypertension with potential application in cardiovascular and kidney disease - from Singapore biotech KBP Biosciences for up to $1.3 billion. 16 October 2023
PHIOGEN Pharmaceuticals, an innovative biotech start-up housed in the Texas Medical Center Innovation Hub and pioneering next-generation bacteriophage-based therapeutics, has appointed Dr Mayukh Das as chief operations officer (COO). 16 October 2023
Interim Phase II data from the Phase II/III Orbit study demonstrate setrusumab resulted in 67% reduction in annualized fracture rate, as well as continuous and meaningful improvements in bone mineral density (BMD) in patients with osteogenesis imperfecta (OI). 16 October 2023
The Lonza subsidiary Synaffix, which is focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, has entered a licensing deal with SOTIO Biotech. 16 October 2023
Swiss biotech firm MoonLake Immunotherapeutics saw its US traded shares rise pre-market, after it announced positive 24-week top-line results from its global Phase II MIRA trial. 16 October 2023
USA-based CNS disease specialist Supernus Pharmaceuticals has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease (PD). 13 October 2023
China-headquartered independent biotech MediLink Therapeutics has entered into a strategic research collaboration and worldwide license agreement with Germany’s BioNTech on the development of a next-generation antibody-drug conjugate (ADC) candidate against human epidermal growth factor receptor 3 (HER3). 13 October 2023
China’s CARsgen Therapeutics has announced the publication of two cases of long-term disease-free survival in the treatment of advanced hepatocellular carcinoma (HCC) with its CAR-GPC3 T-cell therapy. 12 October 2023